City page
Krakow biotech and pharma directory
Krakow is Poland's research-driven biotech capital, home to the country's strongest oncology drug discovery cohort: Ryvu Therapeutics (small-molecule oncology), Captor Therapeutics (targeted protein degradation), OncoArendi Therapeutics (small-molecule), and Selvita's discovery and CRO operations. Jagiellonian University (one of Europe's oldest, with strong life sciences) anchors the academic-industrial coupling. The Krakow Life Sciences Park provides shared infrastructure. Where Warsaw is commercial, Krakow is innovative.
Where does this city read strongest?
Diagnostics (2), Cluster (1), and Therapeutics (1). Most visible records: Diagnostyka S.A., intoDNA S.A., and Jagiellonian Centre of Innovation.
Which standards and public evidence are already visible?
Not yet available.. Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Krakow.
By category
Krakow by category
Jump into a category page filtered to this country only.
Full list
Krakow biotech and pharma directory
5 city records currently match the active filter.
Current review cycle
Diagnostyka S.A.
KrakowPolandDiagnostics
Poland's largest medical diagnostic laboratory network with 156 laboratories, over 1,100 patient collection points, and Warsaw Stock Exchange listing under the ticker DIA.
- Lead
- Jakub SwadzbaChief Executive Officer and Co-Founder
- Scale
- National clinical-diagnostic service delivery
Current review cycle
intoDNA S.A.
KrakowPolandDiagnostics
Krakow molecular diagnostics biotech with the proprietary STRIDE DNA-break detection platform, supplying biomarker services for PARP inhibitors, DDR programs, and companion-diagnostic development.
- Lead
- Magda KordonChief Executive Officer and Co-Founder
- Scale
- Biomarker services operation
Current review cycle
Jagiellonian Centre of Innovation
KrakowPolandCluster
Krakow innovation operator behind Life Science Park laboratory space, biotechnology tenancy, and startup-to-scaleup infrastructure.
- Lead
- Krzysztof KoniecznyPresident of the Management Board
- Scale
- Krakow life-science park operator
Current review cycle
Ryvu Therapeutics
KrakowPolandTherapeutics
Clinical-stage oncology drug discovery and development platform in Krakow focused on small-molecule therapies against emerging cancer targets.
- Lead
- Pawel PrzewiezlikowskiChief Executive Officer and President of the Management Board
- Scale
- Clinical-stage drug discovery
Current review cycle
Selvita
KrakowPolandResearch
Integrated drug discovery and development CRO platform with major research operations in Krakow and a multi-site delivery footprint across Poland. The verified March 2026 record captures current executive leadership and a live preclinical-to-development operating profile.
- Lead
- Bogusław SieczkowskiChief Executive Officer
- Scale
- Multi-site research services platform
FAQ
Frequently asked questions
- What biotech companies are headquartered in Krakow?
- Ryvu Therapeutics (oncology — Phase II in AML), Captor Therapeutics (targeted protein degradation, oncology), OncoArendi Therapeutics (small-molecule oncology), Selvita (drug discovery + CRO services, world's largest pure-play discovery CRO by some metrics), and a growing cohort of biotech spinouts from Jagiellonian University.
- Why is Krakow strong in drug discovery?
- Three factors: Jagiellonian University's deep medicinal chemistry tradition; Selvita pioneering Polish CRO/discovery work in the 2000s and producing alumni who founded Ryvu, Captor, and OncoArendi; competitive operating costs vs Western Europe enabling longer-runway discovery work. Krakow is now the strongest oncology drug discovery cluster in Central and Eastern Europe.
- How does Krakow compare to Warsaw for biotech?
- Krakow = research-intensive drug discovery (Ryvu, Captor, Selvita, OncoArendi) anchored by Jagiellonian University. Warsaw = commercial pharma scale (Polpharma, Adamed, Bioton) and big-pharma Polish HQs. The two are complementary: Krakow for innovation pipeline, Warsaw for partnership and supply.
Related briefs
Briefs that mention Krakow
Polish Biotech & Pharma Landscape 2026: Warsaw, Wroclaw, Krakow
A practical map of the Polish biotech and pharma landscape in 2026 — Warsaw as pharma and regulatory anchor, Wroclaw as innovation belt, Krakow as discovery cluster, plus CDMO, clinical-research, and supply-chain layers — with 39 operators in the directory.
Open briefEuropean Drug Discovery Services 2026: CRO, Medicinal Chemistry, ADMET, DMPK
Where to run European drug discovery services in 2026 — Evotec, Selvita, Charles River Finland, Gubra, Admescope, plus a Swiss + Polish + Nordic tool + platform layer for medicinal chemistry, DMPK, ADMET, and translational research.
Open briefEuropean AI Drug Discovery & Computational Biology 2026: Generative Design, AI Pathology, Computational Chemistry
A practical map of the European AI-enabled drug discovery and computational biology sector in 2026 — generative protein design, AI pathology, computational drug discovery CROs, AI imaging diagnostics, and the operators wiring machine learning into therapeutic pipelines.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.